OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

NCT03661047 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study will be closed due to zero enrollment in over 2 years.

Conditions

Colon Cancer

Interventions

DRUG: AMR101 (VASCEPA, icosapent ethyl)

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]